Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 103

1.

Antibody-drug conjugates: an emerging modality for the treatment of cancer.

Leal M, Sapra P, Hurvitz SA, Senter P, Wahl A, Schutten M, Shah DK, Haddish-Berhane N, Kabbarah O.

Ann N Y Acad Sci. 2014 Aug;1321(1):41-54. doi: 10.1111/nyas.12499.

PMID:
25123209
[PubMed - in process]
2.

Site-specific antibody drug conjugates for cancer therapy.

Panowksi S, Bhakta S, Raab H, Polakis P, Junutula JR.

MAbs. 2014 Jan-Feb;6(1):34-45. doi: 10.4161/mabs.27022.

PMID:
24423619
[PubMed - in process]
Free PMC Article
3.

Antibody-drug conjugates: an emerging concept in cancer therapy.

Chari RV, Miller ML, Widdison WC.

Angew Chem Int Ed Engl. 2014 Apr 7;53(15):3796-827. doi: 10.1002/anie.201307628. Epub 2014 Feb 20.

PMID:
24677743
[PubMed - in process]
4.

Antibody drug conjugates - Trojan horses in the war on cancer.

Iyer U, Kadambi VJ.

J Pharmacol Toxicol Methods. 2011 Nov-Dec;64(3):207-12. doi: 10.1016/j.vascn.2011.07.005. Epub 2011 Aug 6. Review.

PMID:
21843648
[PubMed - indexed for MEDLINE]
5.

Targeted cancer therapy: conferring specificity to cytotoxic drugs.

Chari RV.

Acc Chem Res. 2008 Jan;41(1):98-107. Epub 2007 Aug 18. Review.

PMID:
17705444
[PubMed - indexed for MEDLINE]
6.

Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer.

Junutula JR, Flagella KM, Graham RA, Parsons KL, Ha E, Raab H, Bhakta S, Nguyen T, Dugger DL, Li G, Mai E, Lewis Phillips GD, Hiraragi H, Fuji RN, Tibbitts J, Vandlen R, Spencer SD, Scheller RH, Polakis P, Sliwkowski MX.

Clin Cancer Res. 2010 Oct 1;16(19):4769-78. doi: 10.1158/1078-0432.CCR-10-0987. Epub 2010 Aug 30.

PMID:
20805300
[PubMed - indexed for MEDLINE]
Free Article
7.

Exploring the effects of linker composition on site-specifically modified antibody-drug conjugates.

Albers AE, Garofalo AW, Drake PM, Kudirka R, de Hart GW, Barfield RM, Baker J, Banas S, Rabuka D.

Eur J Med Chem. 2014 Aug 23. pii: S0223-5234(14)00797-1. doi: 10.1016/j.ejmech.2014.08.062. [Epub ahead of print]

PMID:
25176286
[PubMed - as supplied by publisher]
8.

[Design of next generation antibody drug conjugates].

Zhu GD, Fu YX.

Yao Xue Xue Bao. 2013 Jul;48(7):1053-70. Chinese.

PMID:
24133971
[PubMed - in process]
9.

Antibody-drug conjugates for cancer therapy.

Carter PJ, Senter PD.

Cancer J. 2008 May-Jun;14(3):154-69. doi: 10.1097/PPO.0b013e318172d704. Review.

PMID:
18536555
[PubMed - indexed for MEDLINE]
10.

Antibody-drug conjugate technology development for hematologic disorders.

Bander NH, Czuczman MS, Younes A.

Clin Adv Hematol Oncol. 2012 Aug;10(8 Suppl 10):1-16.

PMID:
23072775
[PubMed - indexed for MEDLINE]
11.

Trends in cancer-targeted antibody-drug conjugates.

Bidard FC, Trédan O.

Target Oncol. 2014 Mar;9(1):1-8. doi: 10.1007/s11523-013-0302-9. Epub 2013 Nov 13.

PMID:
24221961
[PubMed - in process]
12.

[Antibody-drug conjugates and their application in the treatment of hematological malignancies].

Lin L, Ding Q, Tang Q, Zhang ZZ, Dai Z, Zhan JB.

Yao Xue Xue Bao. 2012 Oct;47(10):1287-96. Review. Chinese.

PMID:
23289140
[PubMed - indexed for MEDLINE]
13.

The antibody-drug conjugate: an enabling modality for natural product-based cancer therapeutics.

Gerber HP, Koehn FE, Abraham RT.

Nat Prod Rep. 2013 May;30(5):625-39. doi: 10.1039/c3np20113a. Review.

PMID:
23525375
[PubMed - indexed for MEDLINE]
14.

Current Phase II antibody-drug conjugates for the treatment of lymphoid malignancies.

Robak T, Robak E.

Expert Opin Investig Drugs. 2014 Jul;23(7):911-24. doi: 10.1517/13543784.2014.908184. Epub 2014 Apr 7.

PMID:
24708159
[PubMed - in process]
15.

Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies.

Ducry L, Stump B.

Bioconjug Chem. 2010 Jan;21(1):5-13. doi: 10.1021/bc9002019. Review.

PMID:
19769391
[PubMed - indexed for MEDLINE]
16.

Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection.

Polson AG, Calemine-Fenaux J, Chan P, Chang W, Christensen E, Clark S, de Sauvage FJ, Eaton D, Elkins K, Elliott JM, Frantz G, Fuji RN, Gray A, Harden K, Ingle GS, Kljavin NM, Koeppen H, Nelson C, Prabhu S, Raab H, Ross S, Slaga DS, Stephan JP, Scales SJ, Spencer SD, Vandlen R, Wranik B, Yu SF, Zheng B, Ebens A.

Cancer Res. 2009 Mar 15;69(6):2358-64. doi: 10.1158/0008-5472.CAN-08-2250. Epub 2009 Mar 3. Erratum in: Cancer Res. 2010 Feb 1;70(3):1275. Slaga, Dion S [added].

PMID:
19258515
[PubMed - indexed for MEDLINE]
Free Article
17.

Antibody-drug conjugates: current status and future directions.

Perez HL, Cardarelli PM, Deshpande S, Gangwar S, Schroeder GM, Vite GD, Borzilleri RM.

Drug Discov Today. 2014 Jul;19(7):869-81. doi: 10.1016/j.drudis.2013.11.004. Epub 2013 Nov 15.

PMID:
24239727
[PubMed - in process]
18.

Production of site-specific antibody-drug conjugates using optimized non-natural amino acids in a cell-free expression system.

Zimmerman ES, Heibeck TH, Gill A, Li X, Murray CJ, Madlansacay MR, Tran C, Uter NT, Yin G, Rivers PJ, Yam AY, Wang WD, Steiner AR, Bajad SU, Penta K, Yang W, Hallam TJ, Thanos CD, Sato AK.

Bioconjug Chem. 2014 Feb 19;25(2):351-61. doi: 10.1021/bc400490z. Epub 2014 Jan 29.

PMID:
24437342
[PubMed - in process]
19.

Linker technologies for antibody-drug conjugates.

Nolting B.

Methods Mol Biol. 2013;1045:71-100. doi: 10.1007/978-1-62703-541-5_5. Review.

PMID:
23913142
[PubMed - indexed for MEDLINE]
20.

Antibody-drug conjugates for the treatment of cancer.

Flygare JA, Pillow TH, Aristoff P.

Chem Biol Drug Des. 2013 Jan;81(1):113-21. doi: 10.1111/cbdd.12085. Review.

PMID:
23253133
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk